MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 529021 | Name: Alvameline Tartrate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Alvameline Tartrate is a muscarinic M1 receptor agonist and M2/M3 receptor antagonist potentially for treatment of urinary incontinence.

Chemical Structure

Alvameline Tartrate
Alvameline Tartrate
CAS#159792-14-0 (Alvameline Tartrate)

Theoretical Analysis

MedKoo Cat#: 529021

Name: Alvameline Tartrate

CAS#: 159792-14-0 (Alvameline Tartrate)

Chemical Formula: C13H21N5O6

Exact Mass:

Molecular Weight: 343.34

Elemental Analysis: C, 45.48; H, 6.17; N, 20.40; O, 27.96

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
120241-31-8 (Alvameline free base)
Synonym
LU-25-109T; LU-25109T; LU 25 109T; LU 25109T
IUPAC/Chemical Name
5-(2-ethyl-2H-tetrazol-5-yl)-1-methyl-1,2,3,6-tetrahydropyridine (2R,3R)-2,3-dihydroxysuccinate
InChi Key
JHGFYOXAUPXDGA-LREBCSMRSA-N
InChi Code
InChI=1S/C9H15N5.C4H6O6/c1-3-14-11-9(10-12-14)8-5-4-6-13(2)7-8;5-1(3(7)8)2(6)4(9)10/h5H,3-4,6-7H2,1-2H3;1-2,5-6H,(H,7,8)(H,9,10)/t;1-,2-/m.1/s1
SMILES Code
CN1CC(C2=NN(CC)N=N2)=CCC1.O=C(O)[C@H](O)[C@@H](O)C(O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 343.34 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Waldeck K, Larsson B, Sandberg B, Andersson K-. Actions of the new antimuscarinic compound Lu 25-109 on isolated human and pig detrusor. Neurourol Urodyn. 2002;21(1):92-8. PubMed PMID: 11835429. 2: Sveigaard HH, Dalgaard L. Evaluation of blood-brain barrier passage of a muscarine M1 agonist and a series of analogous tetrahydropyridines measured by in vivo microdialysis. Pharm Res. 2000 Jan;17(1):70-6. PubMed PMID: 10714611. 3: Forlenza OV, Spink JM, Dayanandan R, Anderton BH, Olesen OF, Lovestone S. Muscarinic agonists reduce tau phosphorylation in non-neuronal cells via GSK-3beta inhibition and in neurons. J Neural Transm (Vienna). 2000;107(10):1201-12. PubMed PMID: 11129110. 4: Thal LJ, Forrest M, Loft H, Mengel H. Lu 25-109, a muscarinic agonist, fails to improve cognition in Alzheimer's disease. Lu25-109 Study Group. Neurology. 2000 Jan 25;54(2):421-6. PubMed PMID: 10668706. 5: Christensen EB, Andersen JB, Pedersen H, Jensen KG, Dalgaard L. Metabolites of [(14)C]-5-(2-ethyl-2H-tetrazol-5-yl)-1-methyl-1,2,3, 6-tetrahydropyridine in mice, rats, dogs, and humans. Drug Metab Dispos. 1999 Nov;27(11):1341-9. PubMed PMID: 10534320. 6: Jensen KG, Dalgaard L. In vitro metabolism of the M1-muscarinic agonist 5-(2-ethyl-2H-tetrazol-5-yl)-1-methyl-1,2,3,6-tetrahydropyridine by human hepatic cytochromes P-450 determined at pH 7.4 and 8.5. Drug Metab Dispos. 1999 Jan;27(1):125-32. PubMed PMID: 9884321. 7: Sánchez C, Arnt J, Didriksen M, Dragsted N, Moltzen Lenz S, Matz J. In vivo muscarinic cholinergic mediated effects of Lu 25-109, a M1 agonist and M2/M3 antagonist in vitro. Psychopharmacology (Berl). 1998 Jun;137(3):233-40. PubMed PMID: 9683000. 8: Bymaster FP, Carter PA, Peters SC, Zhang W, Ward JS, Mitch CH, Calligaro DO, Whitesitt CA, DeLapp N, Shannon HE, Rimvall K, Jeppesen L, Sheardown MJ, Fink-Jensen A, Sauerberg P. Xanomeline compared to other muscarinic agents on stimulation of phosphoinositide hydrolysis in vivo and other cholinomimetic effects. Brain Res. 1998 Jun 8;795(1-2):179-90. PubMed PMID: 9622623. 9: Müller D, Wiegmann H, Langer U, Moltzen-Lenz S, Nitsch RM. Lu 25-109, a combined m1 agonist and m2 antagonist, modulates regulated processing of the amyloid precursor protein of Alzheimer's disease. J Neural Transm (Vienna). 1998;105(8-9):1029-43. PubMed PMID: 9869334. 10: Sramek JJ, Forrest M, Mengel H, Jhee SS, Hourani J, Cutler NR. A bridging study of LU 25-109 in patients with probable Alzheimer's disease. Life Sci. 1998;62(3):195-202. PubMed PMID: 9488097. 11: Pike BR, Hamm RJ. Activating the posttraumatic cholinergic system for the treatment of cognitive impairment following traumatic brain injury. Pharmacol Biochem Behav. 1997 Aug;57(4):785-91. PubMed PMID: 9259007. 12: Pike BR, Hamm RJ. Chronic administration of a partial muscarinic M1 receptor agonist attenuates decreases in forebrain choline acetyltransferase immunoreactivity following experimental brain trauma. Exp Neurol. 1997 Sep;147(1):55-65. PubMed PMID: 9294403.